On October 1, 2018 Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, reported two additions to its leadership team: Thomas Davis, M.D. as Chief Medical Officer and Derek Meisner, J.D. as General Counsel (Press release, Genocea Biosciences, OCT 1, 2018, View Source [SID1234529854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to advance our lead cancer vaccine, GEN-009 and expand the applications for our novel and proprietary ATLAS platform to demonstrate what we believe are critical advantages in neoantigen identification," said Chip Clark, President & CEO of Genocea. "We believe our emerging pipeline of novel neoantigen vaccine and cell therapy programs holds significant promise, and we believe this promise is the reason we’ve been able to attract such talent to Genocea. Tom and Derek bring a depth of industry expertise and quality of insight that will be invaluable."

Dr. Davis joins Genocea with 20+ years of academic and industry experience in immuno-oncology and cancer drug development. Dr. Davis previously served as Chief Medical Officer of Gadeta B.V., a Dutch cell therapy company pursuing novel cancer targets, where he steered a novel cell therapy technology into first-in human clinical studies. He also previously served as Chief Medical Officer of Celldex, a cancer vaccine company, where he led all aspects of clinical and regulatory development.

Mr. Meisner brings broad legal expertise to Genocea as its first in-house General Counsel. He has extensive experience as a corporate attorney, previously serving as the General Counsel to multiple Boston-based financial services firms, including life science investor RA Capital, as well as serving as Partner at the international law firm K&L Gates and as Branch Chief in the Division of Enforcement of the U.S. Securities and Exchange Commission.

On October 1, 2018 DCprime reported that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect (Press release, DCPrime, OCT 1, 2018, View Source [SID1234531233]). Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel . In the past 15 years he worked in different academic institutes and companies, lastly at Kiadis Pharma where he in his role of Chief Medical Officer was part of the management team that took the company public on Euronext Amsterdam in 2015. Most of the products he worked on are related to specialized therapeutic areas, such as oncology, haematology and transplantation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jeroen Rovers comments: "It is an exciting time to join DCprime, as it’s products are moving further into clinical development. Cell based vaccins will potentially be an additional asset in the immunotherapeutic arsenal to prevent or reduce recurrence of cancer and to improve the of life of people living with cancer."

Erik Manting, CEO of DCprime adds: "The appointment of Jeroen Rovers as Chief Medical Officer marks an important step in the development of DCprime as a company. We are transitioning from a technology-driven company to an organisation focused on achieving clinical results. We have launched an international PhII trial in AML with our lead product DCP-001 and aim to launch additional clinical trials in other cancer types in 2019. With Jeroen on board as an experienced CMO we will further strengthen our infrastructure and capabilities to bring cancer immunotherapeutics to clinic."

On October 1, 2018 Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA) constructs, repoted its presented data in a poster session on Sunday, September 30 at the 4th CRI-CIMT-EATI-AACR International Immunotherapy Conference: Translating Science into Survival in New York, New York (Press release, Exicure, OCT 1, 2018, View Source;p=RssLanding&cat=news&id=2369523 [SID1234529700]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster titled "AST-008, a novel TLR9 agonist SNA, induces abscopal antitumor effects in mouse tumor models" supports the ongoing clinical development of the Company’s proprietary SNA technology and highlights new data showing the effects of Exicure’s technology on mouse tumor models through a systemic immune response.

These data presented in the poster session show that both subcutaneous and intra-tumoral administration of AST-008 into one tumor lesion in the mouse model leads to systemic antitumor activity at a distant, un-injected tumor.

"These new data, along with data from other pre-clinical tumor model studies in combination with an anti-PD-1 antibody, and our recently completed Phase 1 trial support the continued advancement of Exicure’s drug candidate AST-008," said Dr. David Giljohann, Chief Executive Officer of Exicure. "We intend to launch our Phase 1b/2 clinical trial in combination with a checkpoint inhibitor in Q4 of 2018."

On October 1, 2018 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, reported that data from a total of five abstracts will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting from November 7-11, 2018 in Washington, D.C (Press release, TESARO, OCT 1, 2018, View Source [SID1234529719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At this year’s SITC (Free SITC Whitepaper) Annual Meeting, we are excited that several abstracts will be presented highlighting data from our rapidly advancing immuno-oncology portfolio, including an oral presentation of the first clinical data of TSR-022, our anti-TIM-3 antibody, in combination with TSR-042, our anti-PD-1 antibody," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "In addition, data from the GARNET trial of TSR-042 in recurrent non-small cell lung cancer (NSCLC) patients will be featured in a poster presentation. TSR-042 is the foundation of our lung cancer strategy and provides a strategic advantage for TESARO in further developing niraparib, TSR-022, and TSR-033, our anti-LAG-3 antibody."

Please plan to visit TESARO at Booth #333 for information about our pipeline.

Details of TESARO’s oral and poster presentations are as follows (all times local):

TSR-022 (anti-TIM-3)
A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma (AMBER)
Oral presentation; Abstract: 10877; Session: Friday, November 9, 2018, 2:15 PM – 4:50 PM
Poster Number: O21; Location: Hall E, Walter E. Washington Convention Center

Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations
Poster Number: P365; Abstract: 10823; Location: Hall E, Walter E. Washington Convention Center

The antitumor efficacy of TIM-3 blockade in a murine model of sarcoma
Poster Number: P677; Abstract: 10720; Location: Hall E, Walter E. Washington Convention Center

TSR-042 (anti-PD-1)
GARNET: Preliminary safety, efficacy, pharmacokinetic, and biomarker characterization from a Phase 1 clinical trial of TSR-042 (anti-PD-1 monoclonal antibody) in patients with recurrent/advanced NSCLC
Poster Number: P326; Abstract: 10853; Location: Hall E, Walter E. Washington Convention Center

TSR-033 (anti-LAG-3)
A phase 1 dose escalation study of TSR-033, an anti-LAG-3 monoclonal antibody, in patients with advanced solid tumors (CITRINO)
Poster Number: P325; Abstract: 10332; Location: Hall E, Walter E. Washington Convention Center

About TSR-042, TSR-022, and TSR-033

TSR-042 is an investigational humanized anti-programmed death (PD)-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks its interaction with the ligands PD-L1 and PD-L2. TSR-042 is the only anti-PD-1 therapy being studied as monotherapy every 3 weeks for 4 doses then every 6 weeks thereafter. TSR-042 was developed as part of the collaboration between TESARO and AnaptysBio, Inc. This collaboration was initiated in March of 2014, and is focused on the development of monospecific antibody drugs targeting PD-1, TIM-3 (TSR-022), and LAG-3 (TSR-033), in addition to a bi-specific antibody drug candidate targeting PD-1/LAG-3 (TSR-075).

On October 1, 2018 Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that it will participate in the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 in New York (Press release, Keryx Biopharmaceuticals, OCT 1, 2018, View Source/news-releases/news-release-details/keryx-biopharmaceuticals-announces-participation-upcoming-2" target="_blank" title="View Source/news-releases/news-release-details/keryx-biopharmaceuticals-announces-participation-upcoming-2" rel="nofollow">View Source [SID1234529682]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the conference, Keryx will be participating in a 25 minute panel discussion titled Renal Anemia on Tuesday, October 2, 2018 at 3:30 p.m. Eastern time at the Sofitel New York in New York City.

A live audio webcast of both the panel discussion will be accessible from Keryx’s website at View Source within the Investor Relations section under "events and presentations." An archived version of the webcast will be available for at least 15 days following the conclusion of the panel discussion.